Mol Cell Biol. 2016 Aug 15. pii: MCB.00138-16.
Garbacz, WG; Lu, P; Miller, TM; Poloyac, SM; Eyre, NS; Mayrhofer, G; Xu, M; Ren, S; Xie, W
University of Pittsburgh, Pittsburgh, Pennsylvania, USA. The University of Adelaide, Australia.
The common complications in obesity and type 2 diabetes include hepatic steatosis and disruption of the glucose-glycogen homeostasis, leading to hyperglycemia. The fatty acid translocase (FAT/CD36), whose expression is inducible in obesity, is known for its function in fatty acid uptake. Previous work by us and others suggested that CD36 plays an important role in hepatic lipid homeostasis, but the results have been conflicting and the mechanisms were not well understood. In this study, by using the CD36 over-expressing transgenic (CD36Tg) mice, we uncovered a surprising function of CD36 in regulating glycogen homeostasis. Over-expression of CD36 promoted glycogen synthesis and as a result, CD36Tg mice were protected from fasting hypoglycemia. When challenged with high-fat diet (HFD), CD36Tg mice showed unexpected attenuation of hepatic steatosis, increased very-low density lipoprotein (VLDL) secretion, and improved glucose tolerance and insulin sensitivity. The HFD-fed CD36Tg mice also showed decreased levels of pro-inflammatory hepatic prostaglandins and 20-hydroxyeicosatetraenoic acid (20-HETE), a potent vasoconstrictive and pro-inflammatory arachidonic acid metabolite. We propose that CD36 functions as a protective metabolic sensor in the liver under the lipid overload and metabolic stress. CD36 may be explored as a valuable therapeutic target for the management of metabolic syndrome.
The team at Ozgene has over two decades of experience creating customised knockout and knock-in mice for pivotal medical research globally. Over 350 scientific publications are based on research using Ozgene mice.